Results Patient-perceived block duration was significantly increased in treatment group I [hazard ratio (95 % confidence interval [CI]) 0.48 (0.31-0.75); P = 0.001] and treatment group II (hazard ratio (95 % CI): 0.52 (0.33-0.81); P = 0.004) compared to control. The block was extended from a median (95 % CI) of 33.1 (28.4-37.3) to 41.2 (32.4-50.9) and 46.5 (35.8-48.9) hours, respectively. Additionally, patients in treatment group II reported increased time that block provided pain relief, higher patient satisfaction, lower pain scores at rest, and decreased drowsiness and confusion. Conclusion The addition of 1 and 4 mg of dexamethasone to the block injectate significantly increased SSNB duration by 8-13 h compared to control. Level of evidence Therapeutic study, level 1.
Introduction
A previous study [4] demonstrated that the subsartorial saphenous nerve block (SSNB) was as efficacious as the traditional femoral nerve block [9, 18] for postoperative analgesia following bone-tendon-bone (BTB)-anterior cruciate ligament (ACL) reconstruction. With the efficacy of SSNB having been established, this study investigates whether analgesia could be extended by the addition of preservative-free dexamethasone. Previous studies with perineural dexamethasone demonstrated prolonged brachial plexus blocks [5] as well as increased analgesic duration in sciatic nerve blocks [17] . The primary aim was to compare patient-derived SSNB duration for ACL patients
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Purpose Subsartorial saphenous nerve blockade (SSNB) is an effective analgesic alternative to femoral nerve blockade after anterior cruciate ligament (ACL) reconstruction with bone-tendon-bone (BTB) autograft. It was hypothesized that dexamethasone in a SSNB will prolong analgesia, improve pain and satisfaction, and reduce postoperative opioid requirements and side effects. Methods One hundred ninety-five patients undergoing ACL reconstruction with BTB autograft (ages were enrolled. Subjects received SSNB with 13 ml of 0.5 % bupivacaine (control group), 1 mg preservative-free dexamethasone +0.5 % bupivacaine (treatment group I), or 4 mg preservative-free dexamethasone +0.5 % bupivacaine (treatment group II). Subjects received identical perioperative management. On postoperative days 1 and 2, subjects reported perceived block duration, pain scores, satisfaction, opioid use, and side effects. Cox-proportional hazards modelling was used to compare block duration, adjusting for body mass index, age, sex, tourniquet time, American Society of Anesthesiologists classification, and intravenous dexamethasone dose.
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who received either 0.5 % bupivacaine or bupivacaine plus dexamethasone. The primary outcome, patient-perceived block duration, was assessed by the patient's answer to the following question: "When did the nerve block entirely wear off?" It was hypothesized that the dexamethasone would prolong blockade from 6 to 10 h [6, 19] , compared to a control nerve block containing only bupivacaine 0.5 %. Secondary outcomes included reduced postoperative opioid consumption, numerical rating scale (NRS) pain scores on POD 1 and 2, patient satisfaction (as assessed using a 0-10 scale), and opioid side effects (as assessed by the opioidrelated symptom distress scale, ORSDS [21] ).
Materials and methods
On the day of surgery, a co-investigator anesthesiologist approached the patient preoperatively. Eligible patients were all American Society of Anesthesiologists (ASA) class I-III patients, ages 16-65, undergoing ambulatory surgery for ACL reconstruction with BTB autograft. Exclusion criteria were obesity [defined as body mass index (BMI) >35 kg/m 2 ], allergy to study medications, NRS pain scores >3 with frequent opioid use prior to surgery (defined as daily for more than 3 weeks), lower extremity neurological dysfunction, diabetes, patients on steroids or requiring stress dose steroids, or contraindications to dexamethasone use.
Once written informed consent was obtained (patients under 18 signed an assent form, and consent was also obtained from their legal guardian), the investigator opened the sealed treatment envelope, which randomized the patient to the control group (SSNB: 0.5 % bupivacaine plain), treatment group I (SSNB: 0.5 % bupivacaine with 1 mg preservative-free dexamethasone), or treatment group II (SSNB: 0.5 % bupivacaine with 4 mg preservative-free dexamethasone).
Randomizer™, an Excel-compatible randomizing program, was used to create a 1:1:1 random allocation sequence to three parallel treatment arms with a total target enrolment number of 195 patients. Non-study personnel prepared opaque sealed treatment envelopes.
Preoperative procedures
Patients and research assistants were blinded to the treatment groups. Preoperative assessments by blinded research assistants included a baseline sensory examination of the saphenous nerve distribution. A sterile alcohol swab was applied to the medial malleolus of the non-operative and operative legs, and any changes in cold or wet sensation were recorded. Basic demographic data were also collected by patient interview.
Intraoperative procedures
Intravenous midazolam was administered in the operating room for anxiolysis and mild sedation. The SSNB was performed prior to the spinal anaesthetic, under ultrasound guidance using a 6-to 13-MHz linear probe L25x by Sonosite ® . At a distance of no more than 7 cm proximal to the medial condyle [13] , a short-axis view of the sartorius and vastus medialis muscles was obtained with the saphenous nerve identified between the two muscles [4] . Using aseptic technique and under direct ultrasound visualization, a 22-gauge Chiba needle was advanced into the plane of the nerve, and the study injectate was administered. The 13-ml injectate was prepared by the anesthesiologist-investigator in the following fashion:
Control: plain 0.5 % bupivacaine Treatment group I: 0.5 % bupivacaine mixed with 1 mg preservative-free dexamethasone (10 mg/ml) Treatment group II: 0.5 % bupivacaine mixed with 4 mg preservative-free dexamethasone (10 mg/ml).
After nerve block administration, a spinal anaesthetic of 60 mg (4 ml) of 1.5 % mepivacaine was administered using a 27-gauge Whitacre needle. Intravenous propofol infusion was titrated at the anesthesiologist's discretion. All patients received intravenous ondansetron (4 mg), dexamethasone (4 mg), and famotidine (20 mg) for postoperative nausea or vomiting prophylaxis. Intravenous ketorolac (30 mg) was administered at the end of the case. Tourniquet time and surgical duration were also documented.
Postanaesthesia care unit (PACU) follow-ups
In the PACU, NRS pain scores were collected every 30 min, starting at 2.5 h after block injection time, until discharge. Opioid medications were withheld until the patient reported NRS pain scores greater than or equal to 4. The discharge regimen consisted of an oral opioid (taken as needed), a non-steroidal anti-inflammatory drug (NSAID; taken on a regular schedule), and an antiemetic (taken as needed). To determine the duration of the SSNB, patients were educated both at the time of consent and before discharge from the PACU regarding symptoms that might be expected as the nerve block resolved, including an increase in pain intensity and an experience of a full return of sensation in the operative leg. Patients were also educated regarding the saphenous nerve distribution, given a set of alcohol swabs, and shown how to test for sensation about the medial malleolus. The sensory examination was then administered prior to discharge.
Postoperative phone follow-ups
On POD 1 and POD 2, patients were contacted by telephone and asked to answer questions related to NRS pain (at rest, with movement), opioid consumption, and satisfaction with postoperative analgesia. The Optum short form (SF)-8 health survey was administered to assess mental and physical functions [20] . The ORSDS [21] was administered to assess the severity of opioid-associated symptoms, including nausea, vomiting, constipation, and fatigue. Patients were asked to report durations of analgesia, as noted by times at which (1) they first felt pain in their knee, (2) the block stopped providing pain relief, and (3) the block entirely wore off. The duration from block injection time to the time of the patient-perceived block wear-off time was the primary outcome. Usage of anti-emetics and NSAIDs was also recorded. Blinding assessments [2] were performed on POD 2, and patients were asked to guess whether they did or did not receive dexamethasone in the block.
On POD 14, NRS pain scores at rest and with movement were collected via telephone follow-ups.
This double-blinded, randomized controlled trial was approved by the Institutional Review Board (IRB #2012-002) at the Hospital for Special Surgery. It was registered on clinicaltrials.gov on April 25, 2012.
Statistical analysis
Median block duration was estimated using the KaplanMeier method to account for the presence of censored data (i.e. when patients had not experienced the event by the time of their last interview). Block duration measures are reported as medians with 95 % confidence intervals estimated via a log-log transformation. Cox-proportional hazards modelling was used to compare block duration between groups, both with and without covariate adjustment, with results presented as hazard ratios with 95 % confidence intervals. Normality of continuous variables was assessed via inspection of Q-Q plots and histograms. Normally distributed continuous variables are summarized as means with standard deviations, and non-normally distributed continuous variables are summarized as medians with 1st and 3rd quartiles. Categorical variables are presented as counts and percentages. Categorical outcomes with a single value per patient were compared between groups using chi-square or Fisher's exact test, as appropriate. Outcomes with two or more measurements per patient were analysed using regression based on a generalized estimating equations (GEE) approach [16, 22] with an identity link for continuous outcomes and a logit link for binary outcomes. An autoregressive [AR(1)] correlation structure was used for outcomes with three or more measurements per patient. The GEE method accounts for the correlation between repeated measurements on the same patient, where the AR(1) correlation structure assumes a greater degree of correlation among measurements recorded closer in time. A treatment by time interaction term was initially included in all GEE models to test for changes in treatment effect over time. If no evidence of an interaction was found, the model was refit without an interaction term, and results were reported as overall difference in means between groups. All regression models were adjusted for age, sex, BMI, tourniquet time, ASA, and IV dexamethasone dose. Model covariates were chosen based on hypothesized association with the outcomes and included in the final models regardless of statistical significance. Success of blinding was reported as Bang's blinding indices with 95 % confidence intervals for patients and investigators. Bang's blinding index ranges from −1 to 1, where −1 indicates opposite guessing (i.e. all treatment assignment guesses are opposite of actual treatment), 0 indicates perfect blinding, and 1 indicates complete unblinding. All hypothesis tests were two-sided, with statistical significance defined as P < 0.05. Statistical analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC).
The mean ± standard deviation time until the block completely wore off, 18 ± 16 h, was based on Lundblad et al. [15] . A sample size of 59 patients in each of the three groups provided 80 % power at a two-sided alpha of 0.05 to detect an 8-h difference in block duration between each experimental group and the control group, assuming a common within-group standard deviation of 16 h. A total of 195 patients were enrolled to account for a potential 10 % dropout rate.
Results

Patient flow and demographic/intraoperative information
One patient dropped out of the study before data collection was complete, and seven patients were lost to followup (Fig. 1) . One patient underwent an additional surgical procedure, and one did not undergo ACL reconstruction. One patient was noted to have a high BMI in the operating room, did not receive the intervention, and was excluded from the study. Data from 186 patients were used for analysis. There were no significant differences in baseline characteristics among the three groups (Table 1) . Most patients received 4 mg of intravenous dexamethasone. However, one patient in treatment group I and three patients in group II did not receive intravenous dexamethasone. In addition, one patient in treatment group 1 and one patient in treatment group II received 8 mg of intravenous dexamethasone.
Block duration
The primary outcome, patient-perceived block duration, was significantly increased in treatment group I [hazard ratio (95 % CI): 0.48 (0.31-0.75)] and treatment group II [(hazard ratio (95 % CI): 0.52 (0.33-0.81)] compared to control (Fig. 2) . This extended the block from a median (95 % CI) of 33 (28.4-37.3) to 41 (32.4-50.9) (1 mg) and 46.5 (35.8-48.9) (4 mg) hours.
Sensation of returning pain, as determined by the answer to the question of "When did you start having pain in your knee again?", was similar in all groups. Termination of analgesic effect, as determined by the answer to the question of "When did the nerve block stop providing pain relief?", was also similar between the control group and treatment group I but demonstrated a statistically significant difference between the control group and treatment group II (Table 2) .
Pain scores, patient satisfaction, and medication usage
At rest, treatment group II had a lower overall pain score in comparison with control (Table 2 ). There was no difference in pain scores with movement among the three groups. Opioid consumption was also similar in all three groups. Additionally, there was no difference in the adjuvant use of pregabalin, anti-emetics, and NSAIDs (Table 2) .
Patient satisfaction did not differ between treatment group I and the control group. However, it was increased in treatment group II compared to the control group, although the difference in means was relatively small and may not be clinically significant (Table 2 ). There were also significant improvements in the ORSDS components of confusion and drowsiness in treatment group II compared to the control group ( Table 2) .
Administration of the SF-8 survey on POD 1 and POD 2 assessed mental and physical function. No differences in mental component scores or physical component scores were observed among groups (Table 2) .
Blinding assessment
Effective blinding was demonstrated [2] . Most patients, whether they received dexamethasone in the block or not, guessed that they had received the adjuvant.
Discussion
The most important finding of the present study was that low-dose perineural dexamethasone (1 mg) was as effective as a higher dose (4 mg) in providing significantly increased block duration by 8-13 h. This concurs with the findings by Liu et al. [14] , who found that a dose of 1-2 mg or 4 mg dexamethasone as the perineural adjuvant prolonged the analgesic effect in supraclavicular blocks and suggests that the optimal perineural dexamethasone dose can be quite small. Additional important findings in group II versus control were reduction in pain scores, decreased drowsiness and confusion, and increased patient satisfaction.
Review of the literature regarding perineural dexamethasone demonstrates conflicting results. Studies find increased block duration [6, 10, 19] , with a recent Hypertension; N (%) 1 (2) 4 (7) 2 (3) Hyperlipidaemia; N (%) 0 (0) 1 (2) 2 (3) Smoker; N (%) 1 (2) 3 (5) 3 (5) Normal sensation in operative leg; N (%) 61 (98) 61 (100) meta-analysis identifying prolongation of analgesia with lower opioid consumption, specifically in brachial plexus blocks [7] . However, further studies have shown that prolonged analgesic duration can be obtained by the administration of either intravenous or perineural dexamethasone [1, 8] . Rahangdale et al. [17] found no difference in the quality of recovery from foot/ankle surgery following a sciatic nerve block with perineural or intravenous dexamethasone or saline, although duration of analgesia was prolonged in both additive groups compared to placebo. These studies all administered doses of 8-10 mg of dexamethasone. In contrast, Kawanishi et al. [11] , using 4 mg dexamethasone, found that the length of the interscalene sensory block was only extended with perineural administration. Together, these findings are consistent with arguments that large doses (>0.1 mg/kg) of dexamethasone have a systemic mechanism of action that can obscure a locally mediated, perineural effect [3, 7] . The optimal dose for perineural dexamethasone to exert a local effect has yet to be determined. In this study, patients received 4 mg dexamethasone intravenously as an anti-emetic. Total dexamethasone doses were 4 mg (control), 5 mg (treatment group I), and 8 mg (treatment group II). It is unlikely that increasing the total dose from 4 mg (control) to 5 mg (treatment group I) caused the marked block prolongation. However, it is possible that improvements seen only in treatment group II (4 mg perineural dexamethasone; decreased NRS scores at rest, increased time until block stopped providing pain relief, increased patient satisfaction, and improved side effect profile) reflect a systemic effect from using a total of 8 mg dexamethasone.
Since patients received an anti-emetic dose of dexamethasone intraoperatively, one study limitation is that the dose of systemically administered dexamethasone was not rigorously compared to that given perineurally. A study comparing these two methods for the administration of low-dose dexamethasone is needed. Another study limitation is that longer block duration did not translate into reduced opioid consumption or lower pain scores in the 1 mg group compared to control. One explanation is that the SSNB for this study was performed 7-10 cm proximal to the medial condyle in order to minimize the possibility of anesthetizing the vastus component of the femoral nerve. Perhaps the resolution of the block, performed just above the knee itself, occurs in such a way that a significant difference between groups for onset of discomfort cannot be detected. Use of the more proximal mid-thigh adductor canal approach to the saphenous nerve may demonstrate a difference in analgesia between groups.
The clinical relevance of this work lies in the clear utility of the SSNB for pain control following ACL reconstruction with BTB autographs. This study demonstrated that addition of a very small dose of preservative-free dexamethasone (1-2 mg) to the local anaesthetic used for the nerve block will increase this block's duration. Clinically, it is best to use the lowest effective dose of medication so as to avoid potential side effects. The SSNB is particularly well suited for use with additives since it is a sensory block and quadriceps function is spared [12] .
Conclusion
This study compared the outcomes of patients receiving a SSNB with plain bupivacaine, bupivacaine with 1 mg dexamethasone, or bupivacaine with 4 mg dexamethasone for postoperative analgesia following ACL reconstruction using BTB autograft. The addition of both 1 and 4 mg of dexamethasone to the block injectate significantly increased block duration by 8-13 h. Additionally, patients in the 4 mg dexamethasone group reported lower NRS pain scores at rest, improved patient satisfaction and decreased drowsiness and confusion, which may reflect a systemic dexamethasone effect. There was no difference in measurements of NRS pain scores with movement. Medication (NSAIDs, pregabalin) usage and opioid consumption were similar in all three groups.
